Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 11(1): 10955, 2021 05 26.
Article in English | MEDLINE | ID: mdl-34040104

ABSTRACT

The primary hallmark of Parkinson's disease (PD) is the generation of Lewy bodies of which major component is α-synuclein (α-Syn). Because of increasing evidence of the fundamental roles of α-Syn oligomers in disease progression, α-Syn oligomers have become potential targets for therapeutic interventions for PD. One of the potential toxicities of α-Syn oligomers is their inhibition of SNARE-mediated vesicle fusion by specifically interacting with vesicle-SNARE protein synaptobrevin-2 (Syb2), which hampers dopamine release. Here, we show that α-Syn monomers and oligomers cooperatively inhibit neuronal SNARE-mediated vesicle fusion. α-Syn monomers at submicromolar concentrations increase the fusion inhibition by α-Syn oligomers. This cooperative pathological effect stems from the synergically enhanced vesicle clustering. Based on this cooperative inhibition mechanism, we reverse the fusion inhibitory effect of α-Syn oligomers using small peptide fragments. The small peptide fragments, derivatives of α-Syn, block the binding of α-Syn oligomers to Syb2 and dramatically reverse the toxicity of α-Syn oligomers in vesicle fusion. Our findings demonstrate a new strategy for therapeutic intervention in PD and related diseases based on this specific interaction of α-Syn.


Subject(s)
Membrane Fusion/drug effects , SNARE Proteins/antagonists & inhibitors , alpha-Synuclein/pharmacology , Amino Acid Sequence , Amino Acid Substitution , Dopamine/metabolism , Dopamine/pharmacology , Drug Evaluation, Preclinical , Liposomes , Membrane Lipids/metabolism , Models, Molecular , Mutation, Missense , Peptide Fragments/pharmacology , Point Mutation , Protein Binding , Protein Multimerization , Proteolipids/chemistry , Recombinant Fusion Proteins/pharmacology , SNARE Proteins/physiology , Vesicle-Associated Membrane Protein 2/antagonists & inhibitors , Vesicle-Associated Membrane Protein 2/physiology , alpha-Synuclein/chemistry , alpha-Synuclein/genetics , alpha-Synuclein/toxicity
2.
J Biol Chem ; 292(39): 16199-16210, 2017 09 29.
Article in English | MEDLINE | ID: mdl-28798239

ABSTRACT

Tumor cell invasion involves targeted localization of proteins required for interactions with the extracellular matrix and for proteolysis. The localization of many proteins during these cell-extracellular matrix interactions relies on membrane trafficking mediated in part by SNAREs. The SNARE protein syntaxin4 (Stx4) is involved in the formation of invasive structures called invadopodia; however, it is unclear how Stx4 function is regulated during tumor cell invasion. Munc18c is known to regulate Stx4 activity, and here we show that Munc18c is required for Stx4-mediated invadopodium formation and cell invasion. Biochemical and microscopic analyses revealed a physical association between Munc18c and Stx4, which was enhanced during invadopodium formation, and that a reduction in Munc18c expression decreases invadopodium formation. We also found that an N-terminal Stx4-derived peptide associates with Munc18c and inhibits endogenous interactions of Stx4 with synaptosome-associated protein 23 (SNAP23) and vesicle-associated membrane protein 2 (VAMP2). Furthermore, expression of the Stx4 N-terminal peptide decreased invadopodium formation and cell invasion in vitro Of note, cells expressing the Stx4 N-terminal peptide exhibited impaired trafficking of membrane type 1 matrix metalloproteinase (MT1-MMP) and EGF receptor (EGFR) to the cell surface during invadopodium formation. Our findings implicate Munc18c as a regulator of Stx4-mediated trafficking of MT1-MMP and EGFR, advancing our understanding of the role of SNARE function in the localization of proteins that drive tumor cell invasion.


Subject(s)
Adenocarcinoma/metabolism , Extracellular Matrix/metabolism , Fibrosarcoma/metabolism , Munc18 Proteins/metabolism , Neoplasm Proteins/metabolism , Podosomes/metabolism , Qa-SNARE Proteins/metabolism , Adenocarcinoma/pathology , Binding, Competitive , Cell Line, Tumor , ErbB Receptors/metabolism , Extracellular Matrix/pathology , Fibrosarcoma/pathology , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Humans , Matrix Metalloproteinase 14/metabolism , Munc18 Proteins/antagonists & inhibitors , Munc18 Proteins/chemistry , Munc18 Proteins/genetics , Neoplasm Invasiveness , Neoplasm Proteins/antagonists & inhibitors , Neoplasm Proteins/chemistry , Neoplasm Proteins/genetics , Peptide Fragments/chemistry , Peptide Fragments/genetics , Peptide Fragments/metabolism , Podosomes/pathology , Protein Interaction Domains and Motifs , Protein Multimerization , Protein Transport , Qa-SNARE Proteins/chemistry , Qa-SNARE Proteins/genetics , Qb-SNARE Proteins/antagonists & inhibitors , Qb-SNARE Proteins/chemistry , Qb-SNARE Proteins/metabolism , Qc-SNARE Proteins/antagonists & inhibitors , Qc-SNARE Proteins/chemistry , Qc-SNARE Proteins/metabolism , RNA Interference , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Vesicle-Associated Membrane Protein 2/antagonists & inhibitors , Vesicle-Associated Membrane Protein 2/chemistry , Vesicle-Associated Membrane Protein 2/metabolism
3.
J Neurosci Methods ; 278: 57-64, 2017 02 15.
Article in English | MEDLINE | ID: mdl-28025172

ABSTRACT

BACKGROUND: The use of the CRISPR/Cas9 system is becoming widespread, however current studies have predominantly focused on dividing cells. It is currently unknown if CRISPR/Cas9 can be used in a postmitotic setting to examine non-cell autonomous/presynaptic phenotypes in the resulting genetically heterogeneous cell population. NEW METHOD: A single CRISPR/Cas9 lentivirus was used to transfect a high percentage of primary cultured neurons and target synaptobrevin 2 (Syb2, also called VAMP2). RESULTS: Primary hippocampal cultures infected with the Syb2 targeting virus displayed dramatic reductions in Syb2 protein and immunocytochemical staining. In many boutons Syb2 was completely undetected. These cultures recapitulated the known functional phenotypes of Syb2 knockout neurons, which are non-cell autonomous and presynaptic in origin, indicating that Syb2 was knocked out in a large fraction of neurons. COMPARISON WITH EXISTING METHOD(S): Previous methods used multiple viruses or sparse transfection methods and only examined cell autonomous or postsynaptic phenotypes. The current method demonstrates that the CRISPR/Cas9 system can be used to alter network dynamics by removing or lowering the target gene from a majority of cells in the culture. CONCLUSIONS: A combination of CRISPR/Cas9 system and single high efficiency lentivirus infection can be used to examine non-cell autonomous and presynaptic phenotypes in postmitotic neurons.


Subject(s)
CRISPR-Cas Systems , Gene Editing/methods , Hippocampus/metabolism , Neurons/metabolism , Vesicle-Associated Membrane Protein 2/antagonists & inhibitors , Animals , Blotting, Western , Cells, Cultured , Excitatory Postsynaptic Potentials/physiology , Gene Knockout Techniques , Genetic Vectors , HEK293 Cells , Hippocampus/cytology , Humans , Immunohistochemistry , Lentivirus/genetics , Mice , Mice, Inbred C57BL , Miniature Postsynaptic Potentials/physiology , Mitosis , Neurons/cytology , Patch-Clamp Techniques , Vesicle-Associated Membrane Protein 2/genetics
4.
Am J Physiol Heart Circ Physiol ; 301(5): H2028-37, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21926345

ABSTRACT

The present study attempted to evaluate whether soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs) mediate lysosome fusion in response to death receptor activation and contribute to membrane raft (MR) clustering and consequent endothelial dysfunction in coronary arterial endothelial cells. By immunohistochemical analysis, vesicle-associated membrane proteins 2 (VAMP-2, vesicle-SNAREs) were found to be abundantly expressed in the endothelium of bovine coronary arteries. Direct lysosome fusion monitoring by N-(3-triethylammoniumpropyl)-4-[4-(dibutylamino)styryl]pyridinium dibromide (FM1-43) quenching demonstrated that the inhibition of VAMP-2 with tetanus toxin or specific small interfering ribonucleic acid (siRNA) almost completely blocked lysosome fusion to plasma membrane induced by Fas ligand (FasL), a well-known MR clustering stimulator. The involvement of SNAREs was further confirmed by an increased interaction of VAMP-2 with a target-SNARE protein syntaxin-4 after FasL stimulation in coimmunoprecipitation analysis. Also, the inhibition of VAMP-2 with tetanus toxin or VAMP-2 siRNA abolished FasL-induced MR clustering, its colocalization with a NADPH oxidase unit gp91(phox), and increased superoxide production. Finally, FasL-induced impairment of endothelium-dependent vasodilation was reversed by the treatment of bovine coronary arteries with tetanus toxin or VAMP-2 siRNA. VAMP-2 is critical to lysosome fusion in MR clustering, and this VAMP-2-mediated lysosome-MR signalosomes contribute to redox regulation of coronary endothelial function.


Subject(s)
Coronary Vessels/metabolism , Endothelial Cells/metabolism , Endothelium, Vascular/metabolism , Lysosomes/metabolism , Membrane Fusion , Membrane Microdomains/metabolism , Vasodilation , Vesicle-Associated Membrane Protein 2/metabolism , Animals , Bradykinin/pharmacology , Cattle , Cells, Cultured , Coronary Vessels/drug effects , Coronary Vessels/physiopathology , Dose-Response Relationship, Drug , Endothelial Cells/drug effects , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Fas Ligand Protein/metabolism , Fluorescence Resonance Energy Transfer , Immunohistochemistry , Immunoprecipitation , Lysosomal-Associated Membrane Protein 1/metabolism , Lysosomes/drug effects , Membrane Fusion/drug effects , Membrane Microdomains/drug effects , Microscopy, Confocal , NADPH Oxidases/metabolism , Protein Transport , Qa-SNARE Proteins/metabolism , RNA Interference , Superoxides/metabolism , Tetanus Toxin/pharmacology , Time Factors , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Vesicle-Associated Membrane Protein 2/antagonists & inhibitors , Vesicle-Associated Membrane Protein 2/genetics
5.
Chem Commun (Camb) ; 47(6): 1713-5, 2011 Feb 14.
Article in English | MEDLINE | ID: mdl-21203627
6.
J Neurosci ; 27(42): 11366-75, 2007 Oct 17.
Article in English | MEDLINE | ID: mdl-17942731

ABSTRACT

A product of myosin Va mutations, Griscelli's syndrome type 1 (GS1) is characterized by several neurologic deficits including quadraparesis, mental retardation, and seizures. Although multiple studies have not clearly established a cause for the neurologic deficits linked with GS1, a few reports suggest that GS1 is associated with abnormal myelination, which could cause the neurologic deficits seen with GS1. In this report, we investigate whether myosin Va is critical to oligodendrocyte morphology and to myelination in vivo. We found that myosin Va-null mice exhibit significantly impaired myelination of the brain, optic nerve, and spinal cord. Oligodendrocytes express myosin Va and loss of myosin Va function resulted in significantly smaller lamellas and decreased process number, length, and branching of oligodendrocytes. Loss of myosin Va function also blocked distal localization of vesicle-associated membrane protein 2 (VAMP2), which is known to associate with myosin Va. When VAMP2 function was disrupted, oligodendrocytes exhibited similar morphologic deficits to what is seen with functional ablation of myosin Va. Our findings establish a role for both myosin Va and VAMP2 in oligodendrocyte function as it relates to myelination.


Subject(s)
Morphogenesis/physiology , Myelin Sheath/physiology , Myosin Heavy Chains/physiology , Myosin Type V/physiology , Oligodendroglia/cytology , Oligodendroglia/metabolism , Animals , Brain/cytology , Brain/growth & development , Cells, Cultured , Mice , Mice, Knockout , Morphogenesis/genetics , Myelin Sheath/metabolism , Myosin Heavy Chains/deficiency , Myosin Heavy Chains/genetics , Myosin Type V/deficiency , Myosin Type V/genetics , Rats , Rats, Sprague-Dawley , Vesicle-Associated Membrane Protein 2/antagonists & inhibitors , Vesicle-Associated Membrane Protein 2/genetics , Vesicle-Associated Membrane Protein 2/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...